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Introduction: B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted
therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients.
Here, patients with either relapsing-remitting (n = 24) or secondary progressive (n = 6) MS presenting with an
acute clinical relapse were screened for their B cell reactivity to brain antigens and were re-tested three to nine
months later. Enzyme-linked immunospot technique (ELISPOT) was used to identify brain-reactive B cells in
peripheral blood mononuclear cells (PBMC) directly ex vivo and after 96 h of polyclonal stimulation. Clinical severity
of symptoms was determined using the Expanded Disability Status Scale (EDSS).
Results: Nine patients displayed B cells in the blood producing brain-specific antibodies directly ex vivo. Six
patients were classified as B cell positive donors only after polyclonal B cell stimulation. In 15 patients a B cell
response to brain antigens was absent. Based on the autoreactive B cell response we categorized MS relapses into
three different patterns. Patients who displayed brain-reactive B cell responses both directly ex vivo and after
polyclonal stimulation (pattern I) were significantly younger than patients in whom only memory B cell responses
were detectable or entirely absent (patterns II and III; p = 0.003). In one patient a conversion to a positive B cell
response as measured directly ex vivo and subsequently also after polyclonal stimulation was associated with the
development of a clinical relapse. The evaluation of the predictive value of a brain antigen-specific B cell response
showed that seven of eight patients (87.5%) with a pattern I response encountered a clinical relapse during the
observation period of 10 months, compared to two of five patients (40%) with a pattern II and three of 14 patients
(21.4%) with a pattern III response (p = 0.0005; hazard ratio 6.08 (95% confidence interval 1.87-19.77).
Conclusions: Our data indicate actively ongoing B cell-mediated immunity against brain antigens in a subset of
MS patients that may be causative of clinical relapses and provide new diagnostic and therapeutic options for a
subset of patients.
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Multiple Sclerosis (MS) is one of the most frequent
neurological disorders causing disability in young adults
and affects approximately 2.5 million people worldwide
[1,2]. An interplay between both susceptibility genes and
still unknown environmental factors is considered to be
causative of the disease. Due to acute inflammatory de-
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unless otherwise stated.and recovery of function, most patients suffer from a
relapsing-remitting course.
In order to develop new therapeutic strategies and a
better understanding of this autoimmune disorder of the
central nervous system (CNS), intensive research efforts
dealing with the underlying disease pathomechanisms
have been undertaken. For a long time, mainly T cells
were considered as the initiator and perpetuator of
the disease. However, during the last two decades, the
important role of B cells as antigen presenting cells and
producers of autoantibodies in the pathogenesis of MS
has increasingly been appreciated [3-5]. In particular, the
role of B cells in MS is hardly understood. This isral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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oligoclonal IgG of yet unknown specificity are a diagnos-
tic hallmark of MS [6]. Clonally expanded B cells persist
in the CNS of MS patients [7] and antibody deposition
with concomitant complement activation represents
the most frequently observed pattern of demyelination in
MS brain lesions [8]. Consistently, plasmapheresis can be
beneficial in exacerbations in relapsing forms of MS [9].
Although for decades no MS-specific autoantibody has
been identified, the discovery of antibodies against the po-
tassium channel KIR4.1 in a substantial proportion of MS
patients has revived interest in antibody-mediated auto-
immunity in MS [10]. Work performed in MS-like pre-
clinical models suggests a role for B cells in initiating
inflammatory responses in the CNS [11] and treatment
of relapsing-remitting MS (RRMS) patients with the
B cell depleting monoclonal antibody rituximab rapidly
and markedly reduced active CNS inflammation [12]. A
similar effectiveness was shown for alemtuzumab [13]
and ofatumumab [14]. Nonetheless, today there is still
no first-line treatment option in MS that specifically tar-
gets B cells and B cell subsets.
The multiple lines of evidence for a contribution of
B cells to the disease pathogenesis raise the question
whether a sub-typing of patients according to their B cell
response in the peripheral blood is not only possible, but
may also permit the identification of B cell-dependent
MS, thus paving the way for a target-oriented and indi-
vidualized therapy.
To this end, we have recently introduced an assay based
upon the enzyme-linked immunospot technique (ELI-
SPOT) for the detection of CNS antigen-specific B cells in
the blood of patients with MS. These B cells only occurred
in MS patients and were absent in healthy donors and in
patients with other inflammatory and non-inflammatory
neurological diseases as well as other autoimmune disor-
ders [15]. Our previous analyses focused on measure-
ments of the brain antigen-specific B cell response after
96 h of polyclonal stimulation. Here we extend our find-
ings by introducing a direct ex vivo assay for patients with
clinical manifestations of an acute MS relapse. This assay
allowed us to visualize acute ongoing B cell immune
responses to antigens prominent in the CNS in a sub-
group of patients and to correlate this response to clin-
ical relapse parameters.
After binding of a specific antigen to the B cell recep-
tor and its presentation to a corresponding effector T
cell, B cell proliferation and differentiation into plasma
cell precursors and memory B cells occur. Whereas anti-
body producing plasma cells are predominantly located
in the bone marrow after emigration from the lymphatic
follicles, resting B lymphocytes recirculate in the body
and can be converted into antibody-producing plasma
cells with the help of polyclonal stimulation in vitro.Only in the context of a relapse and at the stage of the
emigration from the lymphatic follicles to the bone mar-
row, plasma cells become detectable in the blood and
can be directly analyzed for CNS specificity.Material and methods
Patients
Thirty patients that were diagnosed with MS according
to the 2005 or 2010 McDonald criteria [16], respectively,
and undergoing an acute MS relapse were included in
the study. Aggravation of persistent disabilities or new
clinical symptoms were present for at least 24 h. Exclusion
criteria comprised severe accompanying systemic or psy-
chiatric disorders as well as a history of other autoimmune
diseases. Subjects who had undergone plasmapheresis or
received anti-B cell therapy were also excluded. The co-
hort of patients analyzed in this study contained both the
RRMS (n = 24) and the secondary progressive (SPMS)
(n = 6) subtype of MS. Details on all patients are provided
in Table 1. The research protocol was approved by the
institutional ethics committees of the Universities of
Cologne and Wuerzburg. For the evaluation of disease se-
verity the Expanded Disability Status Scale (EDSS) was
used [17]. Additionally, we employed the tool MS Curves,
which is based on the international MSBase Registry
and allows the assessment of the individual disease se-
verity [18]. Results are presented as percentiles and
evaluated by means of EDSS and time since disease on-
set in comparison to a large cohort of patients with the
same disease duration.
Twenty-two patients had other neurological or other
inflammatory neurological diseases (OND/OIND) in-
cluding one patient with global amnesia, one patient
with a psychogenic gait disorder, three patients with
headaches, one patient with myopathy, one patient with
myasthenia gravis, one patient with epilepsia, three pa-
tients with Parkinson’s disease, one patient with poly-
neuropathy, one patient with Guillain-Barré syndrome,
one patient with stroke, one patient with subarachnoid
hemorrhage, one patient with amyotrophic lateral scler-
osis, one patient with neuroborreliosis, one patient with
Ménière’s disease, one patient with vestibular neuritis,
one patient with somatoform pain disorder and two pa-
tients with nystagmus.
All patients gave written informed consent and were re-
cruited from a routine clinical care unit at the Depart-
ments of Neurology, University Hospitals of Cologne and
Wuerzburg and the Caritas-Krankenhaus Bad Mergent-
heim. Serum samples from healthy donors were obtained
from Cellular Technology Limited (Shaker Heights, OH).
Peripheral blood mononuclear cells (PBMC) from healthy
donors were obtained from volunteers at the participating
institutions after written informed consent.
Table 1 Demographic and disease characteristics of the patient cohort
Pattern Patient no. RRMS/SPMS Sex (f/m) Age at time of
relapse (yrs)
Age at time of
diagnosis (yrs)
Relapse
EDSS*
Treatment
at time of
relapse
Remission
EDSS*
Treatment
at time of
remission
MS severity
(percentile)‡
I 1 RRMS f 19 17 3.0 GA 2.0 GA 71
I 2 RRMS f 30 15 4.0 IFN 3.0 IFN 51
I 3 RRMS f 18 17 4.0 None 4.0 None 91
I 4 RRMS f 42 27 6.0 GA 4.0 GA 66
I 5 RRMS f 32 32 3.0 None 2.5 None 81
I 6 RRMS f 29 29 4.5 IFN 4.0 IFN 91
I 7 RRMS f 24 24 2.0 None 1.5 None 51
I 8 RRMS f 32 32 4.0 None 2.0 None 72
I 9 SPMS f 25 20 4.0 FM 4.5 None 91
II 10 RRMS f 22 21 2.0 IFN 2.0 NA 73
II 11 RRMS f 47 47 3.5 None 2.0 IFN 72
II 12 RRMS f 34 31 4.0 None 3.0 IFN 79
II 13§ RRMS f 59 40 6.0 None / / /
II 14 SPMS m 36 32 6.0 Mitox 5.0 Mitox 92
II 15 SPMS f 53 50 5.5 None 5.5 None 93
III 16 RRMS f 32 32 2.0 None 2.0 IFN 73
III 17 RRMS f 49 38 6.0 None 6.0 FM 91
III 18 SPMS m 52 37 5.5 None 5.5 None 80
III 19§ RRMS f 38 23 6.5 None / / /
III 20 RRMS f 48 47 4.0 IFN 3.5 IFN 91
III 21 SPMS m 52 41 2.5 GA 2.5 FM 51
III 22 SPMS f 54 35 7.5 None 7.0 None 92
III 23 RRMS m 40 40 2.0 None 2.0 IFN 72
III 24 RRMS m 61 61 2.0 None 4.0 IFN 91
III 25 RRMS f 31 30 2.0 IFN 1.0 IFN 38
III 26 RRMS f 21 21 3.5 None 1.0 IFN 37
III 27 RRMS f 18 18 6.0 None 1.5 None 51
III 28 RRMS f 45 45 2.0 None 2.0 None 72
III 29 RRMS m 52 27 4.5 None 4.5 None 66
III 30 RRMS f 43 43 6.0 FA 6.0 FA 94
EDSS = Expanded Disability Status Scale; FA = fumaric acid; FM = fingolimod; GA = glatiramer acetate; IFN = interferon-β; Mitox =mitoxantrone; NA = natalizumab;
RRMS = relapsing-remitting MS; SPMS = secondary progressive MS.
*Scores on the EDSS range from 0 to 10, with higher scores indicating a greater degree of disability.
‡MS severity refers to the percentile rank of each individual study patient compared to a matched MS cohort of the MSBase Registry. Values were determined
using MS Curves [18].
§These patients were lost to follow-up.
Hohmann et al. Acta Neuropathologica Communications 2014, 2:138 Page 3 of 11
http://www.actaneurocomms.org/content/2/1/138Enzyme-linked immunospot technique (ELISPOT)
PVDF membrane 96-well ELISPOT plates (Merck
Millipore, Darmstadt, Germany) were coated overnight
with fresh frozen whole normal human brain lysate
(30 μg/ml; Novus Biologicals, Littleton, CO), dissolved in
sterile phosphate-buffered saline (PBS). We deliberately
chose whole brain lysate as antigenic target taking into
account that each individual patient recognizes a multi-
tude of different tissue antigens. We suggest that the
use of single antigens would have been counterintuitivealso following the epitope spreading hypothesis of MS.
Therefore, and particularly from a clinical point of view,
the approach presented here should be the most feasible.
Coating with 10% fetal bovine serum (FBS; Biochrom,
Berlin, Germany) in sterile PBS served as negative control,
respectively. The ELISPOT findings were controlled for
the quantitative frequency of B cells in each sample
by including measurements for total IgG in each donor.
To this end, plates were coated with anti-human Igκ
(SouthernBiotech, Birmingham, AL) at 10 μg/ml. Both
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were titrated to their optimal concentration for use in B
cell ELISPOTassays. After PBMC isolation from the blood
by Ficoll-Paque (GE Healthcare Europe GmbH, Freiburg,
Germany) density gradient centrifugation, PBMC were
diluted in complete RPMI medium consisting of RPMI-
1640 (Lonza, Cologne, Germany) and 10% FBS, 1%
L-glutamine (Sigma, Schnelldorf, Germany) and 1% peni-
cillin/streptomycin (Sigma) to a concentration of 3 × 106
cells/ml. Plates were blocked with 10% FBS in sterile PBS
for 2 h at room temperature. For direct ex vivo testing 3 ×
105 PBMC were plated per well and afterwards incubated
for 24 h at 37°C and 7% CO2. In order to stimulate B cells
polyclonally, PBMC were cultured at a concentration of
3 × 106 cells/ml for 96 h in complete RPMI-1640
medium that contained β-mercaptoethanol (Sigma), the
toll-like receptor 7/8 agonist R-848 (Enzo Life Sciences,
Inc., Farmingdale, NY) and IL-2 (Peprotech, Hamburg,
Germany). For testing of polyclonally stimulated B cells
one million cells were plated per well and incubated for
26 h at 37°C and 7% CO2. Biotinylated anti-human IgG
(Hybridoma Reagent Laboratory, Baltimore, MD) di-
luted in 1% bovine serum albumin (BSA) solution was
used as a detection antibody at 0.2 μg/ml. For the direct
ex vivo testing biotinylated anti-human IgM (Hybrid-
oma Reagent Laboratory) at a concentration of 0.05 μg/
ml was additionally used. All plates were developed with
Vector Blue substrate (Vector Laboratories, Burlingame,
CA) after incubation with streptavidin-alkaline phos-
phatase (AP) (Dako, Glostrup, Denmark) at 1:1000 dilu-
tion. Spots were analyzed on an ImmunoSpot® Series 6
Analyzer (Cellular Technology Limited).
Enzyme-linked immunosorbent assays (ELISA)
ELISA plates (Thermo Scientific, Schwerte, Germany)
were coated overnight with whole normal human brain
lysate (Novus Biologicals; 10 μg/ml) or anti-human Igκ
(SouthernBiotech; 2.5 μg/ml), respectively, both diluted
in PBS or with PBS alone. As for the ELISPOT assay,
whole normal human brain lysate and anti-human Igκ
were titrated to their optimal concentration for use in
the antibody ELISA. Plates were blocked with 10% FBS
in PBS containing 0.05% Tween 20 for 2 h at room
temperature. The plates were incubated overnight with
serum at 4°C. All serum samples were diluted 1:400 in
10% FBS solution containing 0.05% Tween 20 deter-
gent. Biotinylated anti-human IgG (Hybridoma Reagent
Laboratory) diluted in 0.5% FBS/0.05% Tween 20 solu-
tion was used as a detection antibody at 0.05 μg/ml. All
plates were developed with tetramethylbenzidine sub-
strate (eBioscience, Frankurt, Germany) after incubation
with streptavidin-horseradish peroxidase (eBioscience)
at 1:1000 dilution. The reaction was stopped with
0.16 M sulphuric acid and the optical density (OD) inthe wells was read at 450 nm using a Perkin Elmer
Victor 3 1420 Multilabel Counter and Wallac 1420 soft-
ware version 3.00 revision 5.
Statistical analysis
The cut-off value for a positive B cell response measured
directly ex vivo was determined in a cohort of n = 17
healthy donors and was set to > 1.6 spots (mean value +
3 standard deviations). Twelve of the healthy donors
were retested on the consecutive day with similar results
to account for day-to-day variation. The cut-off value for
a brain antigen-specific B cell response after polyclonal
stimulation was set to > 4.5 spots as previously established
[15]. Serum samples were considered positive when the
OD was at least five standard deviations above the mean
value of a cohort of 69 healthy control donors. The char-
acteristics of the patients and their disease were compared
among the groups according to the B cell response status
with the use of the Wilcoxon rank-sum test, which was
also used to determine differences in spot size morph-
ology. The cumulative risk of the development of a MS
relapse was calculated for each group according to the
Kaplan–Meier method, and differences between the groups
were evaluated in a univariate analysis with the log-rank
test. The Cox proportional-hazards model was used to as-
sess the predictive value of a positive brain-specific B cell
response. The relative risk of the development of a MS re-
lapse is expressed as a hazard ratio and 95% confidence
interval. P-values of less than 0.05 were considered to indi-
cate statistical significance.
Results
PBMC from 30 patients with MS experiencing an acute
relapse were analyzed for their response to brain antigen
using the ELISPOT technique. In order to differentiate
between an acute and a memory B cell response, we in-
troduced two different assay types. In a direct ex vivo
approach PBMC were incubated on the plates for 24 h
immediately after separation from the blood sample with-
out any prestimulation. Alternatively, PBMC were tested
after 96 h of polyclonal stimulation with R-848, IL-2 and
β-mercaptoethanol, which is an established method for
the activation of resting memory B cells [19]. Secreted
antibodies were captured on the ELISPOT plates and visu-
alized as spots that corresponded to the numbers of brain
antigen-specific B cells.
Distinct size morphology of B cell spots produced directly
ex vivo and after polyclonal stimulation in ELISPOT assays
In a total of nine patients brain antigen-specific B cells
could be detected in the blood directly ex vivo and after
polyclonal stimulation (Table 2). We compared the morph-
ology of spots produced directly ex vivo and after poly-
clonal stimulation using a specialized ImmunoSpot® image
Table 2 Distribution of B cell response patterns in
patients experiencing an acute MS relapse*
Variable Pattern I Pattern II Pattern III
No. of patients 9 6 15
Age – yrs
Mean 27.9 ± 7.4 41.8 ± 13.7 42.4 ± 12.4
Range 18-42 22-59 18-61
Female sex – no. (%) 9 (100) 5 (83.3) 10 (66.7)
EDSS in remission†
Mean 3.1 ± 1.1 3.5 ± 1.7‡ 3.5 ± 2.0‡
Range 1.5-5.0 2.0-5.5 1.0-7.0
MS severity¶
Mean 73.9 ± 16.0 81.8 ± 10.1‡ 71.4 ± 20.2‡
Range 51-91 72-93 37-94
RRMS/SPMS 8/1 4/2 12/3
EDSS = Expanded Disability Status Scale; RRMS = relapsing-remitting MS;
SPMS = secondary progressive MS; SD = standard deviation.
*Plus-minus values are means ± SD.
†Scores on the EDSS range from 0 to 10, with higher scores indicating a
greater degree of disability.
‡One patient was lost to follow-up.
¶MS severity refers to the percentile rank of each individual study patient
compared to a matched MS cohort of the MSBase Registry. Values were
determined using MS Curves [18].
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were much more distinct and significantly smaller than
spots produced after 96 h of polyclonal stimulation (com-
pare a mean spot size of 0.008282 mm2 ± 0.00852 mm2 to
0.033343 mm2 ± 0.052619 mm2; p < 0.001) (Figure 1).
These results underline the notion that spots detected
directly ex vivo correspond to antibodies produced by
recently activated and still recirculating plasma cells,
while spots produced after polyclonal stimulation are
derived from resting memory B cells that produce sig-
nificantly larger spots following in vitro reactivation.
Brain-reactive antibodies are detectable in the serum of
patients experiencing an acute clinical relapse of MS and
displaying a positive B cell ELISPOT response directly ex vivo
A positive response in directly ex vivo performed B cell
ELISPOT assays should correspond to in vivo ongoing B
cell (re)activation characterized by the secretion of anti-
bodies by plasma cells. To confirm this assumption, we
additionally obtained serum samples from n = 12 patients
of our cohort during relapse and performed ELISA analysis
for the detection of brain-reactive antibodies. Results are
shown in Table 3. Of the 12 patients, four were character-
ized by a positive response in directly ex vivo performed B
cell ELISPOT assays. These patients also displayed CNS
antigen-specific antibodies in the serum as measured by
ELISA. All of the eight patients that were tested negative in
the directly ex vivo performed ELISPOT were also tested
negative in the ELISA.Ongoing brain-specific B cell activity is detectable in the
blood in a subset of patients with an acute disease relapse
In addition to the nine patients that showed a positive B
cell response both directly ex vivo and after polyclonal
stimulation, we identified six of 30 patients that did not
show any B cell activity associated with the relapse, but
were classified as B cell positive donors only after poly-
clonal stimulation. The remaining 15 of 30 patients
displayed brain antigen-specific B cells neither in direct
ex vivo assays nor after 96 h of stimulation. These data
suggest that the MS patients tested in our study fall into
three different categories, depending on the presence of
an actively ongoing and/or CNS antigen-specific mem-
ory B cell response in the blood. These categories are
summarized as “patterns” in Tables 1 and 2 and Figure 2.
No significant differences were found between the pat-
terns in relation to relapse or disease severity (Table 2).
However, patients who were classified as “pattern I” with
a positive B cell response both directly ex vivo and after
polyclonal stimulation were significantly younger than
the cohort of patients represented by both pattern II and
III (p = 0.003). In order to delineate that the CNS antigen-
specific B cell response was not a transient phenomenon,
but a characteristic feature of a disease subtype, we retested
21 MS patients in clinical remission three to nine months
after relapse. In 17 of 21 patients the CNS antigen-specific
B cell response detected after polyclonal stimulation was
comparable to the results obtained during relapse. Four pa-
tients who had been tested negative initially, now showed a
positive response. Loss of a brain antigen-specific B cell re-
sponse in previously positive patients was not observed.
Importantly, the formerly evident B cell activity in nine of
30 patients as measured directly ex vivo was absent in re-
mission. Brain antigen-specific B cells were also absent dir-
ectly ex vivo in healthy donors (n = 17) and patients with
other neurological or other inflammatory neurological dis-
eases (n = 22).
Association between the development of brain-specific B
cell responses in the blood and acute disease reactivation
One interesting finding pertained to a patient who ori-
ginally did not display any CNS antigen-specific B cell
responses directly ex vivo and after polyclonal stimulation.
In this patient clinical examination three months after re-
lapse revealed a recovery of function and no signs for a
renewed clinical disease exacerbation despite the persist-
ence of paresthesia. However, a positive brain antigen-
specific B cell response was evident in direct ex vivo
ELISPOT testing indicating recent immune reactivation.
Ten days later the patient was admitted to the hospital
with symptoms of a clinical relapse including deficits in
visual, cerebellar, sensory as well as motor functions. ELI-
SPOT analysis confirmed the presence of plasma cells
actively secreting brain antigen-reactive antibodies. The
Figure 1 Morphology of B cell spots measured directly ex vivo and after polyclonal stimulation. The histogram shows the differences in
the distribution of B cell spots measured directly ex vivo (black bars) or after 96 h of polyclonal stimulation (colored bars) in ELISPOT assays. The
dashed lines indicate the spot size means in the two groups. A total of 524 spots were analyzed directly ex vivo compared to 2307 spots after
polyclonal stimulation using the ImmunoSpot® software version 5.1.36 Professional DC. The images show representative wells for assays
performed directly ex vivo or after polyclonal stimulation. The numbers in the left upper corner indicate the spot counts for the two individual
wells. The mean spot size measured directly ex vivo was 0.008 mm2 compared to 0.033 mm2 after polyclonal stimulation. Minimum spot sizes
were comparable. The maximum spot size was 0.070483 mm2 in direct ex vivo assays compared to a size of 0.442321 mm2 measured after
polyclonal stimulation.
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during which we were able to demonstrate the disappear-
ance of brain antigen-specific plasma cells from the blood.
At the same time, a brain antigen-specific memory B cell
response became detectable (Figure 3). The dramatic drop
in the number of B cell spots measured directly ex vivo
and after polyclonal stimulation within four days between
the third and fourth measurement may be explained either
by the high dose intravenous glucocorticoid therapy that
was administered at the time point of relapse for threeconsecutive days [20] and/or by the migration of the auto-
reactive B cells into the target tissue, that is the CNS.
A positive brain-specific B cell response in the blood is
predictive of a subsequent relapse
The association between a positive brain-reactive B cell
response in the blood in direct ex vivo assays and the de-
velopment of a consecutive relapse as shown for one case
in Figure 3 suggests that the presence of brain-reactive B
cells in the blood could be linked to a higher relapse rate.
Table 3 Measurements of brain-specific serum antibodies
by ELISA
Patient
no.
Direct
ex vivo
ELISPOT
response
[spot number]
OD SD OD SD OD
brain
antigen/
OD total
IgG
Brain
antigen*
Brain
antigen
Total
IgG
Total
IgG
1 26.0 ± 4.2 1.593 0.136 2.748 0.04 0.58
2 9.0 ± 6.4 0.974 0.094 2.609 0.084 0.373
3 86.5 ± 41.7 0.852 0.107 2.693 0.049 0.316
4 13.0 ± 2.8 1.231 0.084 2.558 0.132 0.48
10 0.0 ± 0.0 0.468 0.014 2.92 0.086 0.16
11 0.0 ± 0.0 0.437 0.034 2.636 0.024 0.166
12 0.0 ± 0.0 0.108 0.000 2.673 0.024 0.04
16 0.0 ± 0.0 0.235 0.057 2.608 0.042 0.09
17 0.0 ± 0.0 0.576 0.013 2.724 0.032 0.211
18 0.0 ± 0.0 0.147 0.034 2.837 0.112 0.052
20 0.0 ± 0.0 0.369 0.047 2.729 0.12 0.135
22 0.0 ± 0.0 0.658 0.060 2.783 0.033 0.236
ELISA = enzyme-linked immunosorbent assay; ELISPOT = enzyme-linked
immunospot technique; OD = optical density; SD = standard deviation.
*All samples were tested in duplicate wells and are represented as mean
medium-subtracted values. The cut-off value for a positive response was
calculated from the means of a group of 69 healthy control donors + 5 SD (OD
brain antigen/OD total IgG > 0.307).
Figure 2 Representative ELISPOT wells of the three different CNS ant
antigen-specific B cell response directly ex vivo and after polyclonal stimula
Pattern II: positive brain antigen-specific B cell response only after polyclon
brain antigen-specific B cell responses at any time point. Images and patte
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displayed a brain-reactive B cell response in the blood dir-
ectly ex vivo and after polyclonal stimulation (pattern I),
n = 5 patients that displayed brain-reactive B cells only
after polyclonal stimulation (pattern II) and n = 14 pa-
tients with a negative B cell response in both assays (pat-
tern III). The patients were followed for a period of ten
months and the time to the next relapse after initial test-
ing was recorded. Data are summarized in Table 4. The
Kaplan-Meier plot shows that the relapse-free interval in
patients that were tested positive in direct ex vivo ELI-
SPOT assays was significantly shorter than in patients that
were classified as pattern II or III (p = 0.0005) (Figure 4).
There was no significant difference between patients with
pattern II versus pattern III (p = 0.348). The hazard ratio
for the development of a consecutive relapse in the setting
of a positive direct ex vivo brain-reactive B cell response
in the blood (pattern I) compared to patients with pattern
II or III was 6.08 (95% confidence interval 1.87-19.77).
Discussion
In the pathogenesis of MS, multiple lines of evidence in-
dicate an important role of B cells and autoantibodies
[21-24]. For decades, intensive research efforts were made
to identify the target antigen in MS, but antibodies against
myelin components or other structures prominent in theigen-specific B cell response patterns. Pattern I: positive brain
tion during relapse, persisting memory B cell response in remission.
al stimulation both in relapse and remission. Pattern III: absence of
rn classifications are representative for a study cohort of 30 patients.
Figure 3 ELISPOT results of a patient showing a conversion from pattern III to pattern I. Panel A shows the number of B cell spots
measured in ELISPOT assays directly ex vivo and after 96 h of polyclonal stimulation in an individual patient on six consecutive time points. The
severity of clinical disease is represented by the EDSS score that is referred to by the line graph. Representative well images of four different time
points are shown in Panel B depicting the development of a brain antigen-specific B cell response in the course of the disease.
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diseases and/or healthy individuals [4,25]. The assump-
tion that antibodies are pathogenic in the development
of MS is mainly supported by histopathological findings
that provided evidence for the frequent deposition ofimmunoglobulins and complement factors in MS brain
lesions [8]. In the past an association between the neuro-
pathological pattern II defined by Lucchinetti et al. and a
benefit from plasma exchange was suggested [26] and
treatment with the B cell-specific monoclonal antibodies
Table 4 Numbers of patients at risk in the different B cell
response groups in the Kaplan-Meier analysis
Time [months] Pattern I Pattern II Pattern III
0 8 5 14
1 7 5 14
2 7 5 14
3 5 5 14
4 4 3 14
5 3 3 12
6 2 3 12
7 2 3 12
8 1 3 12
9 1 3 11
10 1 3 11
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http://www.actaneurocomms.org/content/2/1/138rituximab, alemtuzumab or ofatumumab were effective in
ameliorating disease severity by means of reduction in the
number of total gadolinium-enhancing magnetic reson-
ance imaging (MRI) lesions as well as lower annualized
relapse rates [12-14]. It has initially been suggested that in
particular antibodies against myelin oligodendrocyte
glycoprotein (MOG) and myelin basic protein (MBP)
were predictive of a conversion from a clinically-isolated
syndrome (CIS) to clinically definite MS [27]. However, a
subsequent corroboration of these results failed [28]. Here
we show that the presence of a brain-specific memory B
cell response in the blood as measured by ELISPOT wasFigure 4 Kaplan–Meier estimates of the risk of a MS relapse
according to the presence of brain-specific B cells in the blood.
P = 0.0005 for the comparison between patients who were tested
positive for direct ex vivo brain-specific B cells (pattern I) and patients
who were tested negative (patterns II and III).associated with an increased risk of the development of a
MS relapse.
In our previous work we have demonstrated that the de-
tection of brain antigen-specific B cells in the PBMC popu-
lation permitted the identification of a B cell-dependent
subtype of MS [15]. These data were in line with earlier re-
ports that showed the presence of proteolipid protein
(PLP)- and MOG-specific B cells in the blood and cerebro-
spinal fluid (CSF) of patient with MS using the ELISPOT
approach [29,30]. The data presented here extend these
findings not only by presenting the predictive value of this
test, but also by the introduction of a direct ex vivo assay
that indicated actively ongoing disease and was associated
with clinical disease reactivation in a fraction of patients. It
is tempting to speculate that the presence of brain-reactive
B cell responses in the blood can be used to subdivide
MS patients into different categories as suggested in the
current study. A categorization of patients has already
been done following different patterns of demyelination
in brain lesions and the most frequently observed pat-
tern was characterized by the deposition of antibodies.
Interindividual heterogeneity in the patterns of demyelina-
tive pathology has been suggested [8]. Our data support
this concept, but imply that there might also be intraindi-
vidual heterogeneity in regard to the brain-specific B cell
response over the course of the disease.
Acute clinical relapses of MS often lead to the deteri-
oration of clinical symptoms and the failure of functional
CNS systems. As yet, the evidence-based standard treat-
ment for MS relapses is a high-dose intravenous gluco-
corticosteroid pulse therapy. Since relapse treatment can
only be initiated when new clinical symptoms of MS are
evident and persist, there is always a risk of the develop-
ment of irreversible deficits. The ability to detect relapses
before they become clinically evident and their consecu-
tive early treatment would provide an option to prevent
the accumulation of CNS damage. A subtyping of blood
immune responses as suggested here might be one pos-
sible option along these lines. Even if the CSF is also rela-
tively easy to access and it might be argued that immune
responses in the CSF reflect the pathogenic processes in
the CNS more closely, the risks of side effects and the eth-
ical problems with exposing patients to repeated spinal
taps emphasize the clinical and practical advantage of a
test that can be performed on peripheral blood.
Conclusion
The data presented here strengthen the central role of
B cells in the immune pathogenesis of MS. It is conceiv-
able that our results will help to identify patients with
B cell-/antibody-dependent MS and relapses, thereby
guiding the development and use of B cell-directed thera-
peutic strategies. It remains to be elucidated if the detec-
tion of recirculating B cells that produce CNS-specific
Hohmann et al. Acta Neuropathologica Communications 2014, 2:138 Page 10 of 11
http://www.actaneurocomms.org/content/2/1/138antibodies ex vivo will allow the diagnosis of MS reactiva-
tion even before the occurrence of clinically evident symp-
toms, which would help to facilitate the initiation of early
treatment that could potentially include plasmapheresis
[26]. Finally, the detection of antibody-producing B cells
in MS patients corroborates the autoimmune hypothesis
of the disease and its association with clinical disease
parameters.
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